| |
| 岡 慎一 |
国立国際医療研究センター
エイズ治療・研究開発センター長 |
| HIV感染症、臨床ウイルス学、多施設共同臨床試験 |
| CD4+ count-guided interruption of antiretroviral treatment.The Smart Study Group (Oka S as a principal investigator of the Sydney Regional Coordinating Center). N Engl J Med 355: 2283-2296, 2006 |
| Adaptation of HIV-1 to HLA I. Kawashima Y, Pfafferott K, Duda A, Matthews P, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Kizumi H, Kuse N, Oka S, Brumme Z, Brumme C, Brander C, Allen T, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Heckerma D, Frater J, Prendergast A, Crawford H, Leslie A, Prado J, Ndung’u T, Phillips R, Harrigan R, Walker B, Takiguchi M, and Goulder P. Nature 458: 641-645, 2009 |
| Interleukin-2 therapy in patients with HIV infection. INSIGHT-ESPRIT Study Group (Oka S as a Regional Principal Investigator). N Engl J Med 361:1548-59, 2009. |
|
| |
| 河上 裕 |
慶應義塾大学医学部 先端医科学研究所 細胞情報研究部門・所長・教授
|
| 腫瘍学・免疫学・内科学 |
| Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T and Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 91(9):3515-1519,1994 |
| Rosenberg SA, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S, Restifo N, Dudley M, Schwarz S, Spiess P, Wunderlich J, Parkhurst M, Kawakami Y, Seipp C, Einhorn J and White D. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4(3):321-327,1998 |
| Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during EMT of cancer cell. Cancer Cell. 16(3):195-206,2009 |
|
| |
| 豊島 聰 |
公益財団法人日本薬剤師研修センター・理事長
|
| レギュラトリーサイエンス、免疫学 |
| Effective global drug development strategy in consideration of ethnic factors for regulatory approval in Japan. Ichimaru K, Toyoshima S, Uyama Y. Clin Pharmacol Ther. 2010; 87(3): 362-366 |
| Use of Biomarker in Drug Development-Japanese Perspectives. Uyama Y, Ishiguro A, Nakamura H, Toyoshima S. John Wiley & Sons, Inc. 2012, 269-287 |
| 「疾病と病態生理」豊島 聰他編著、南江堂 (2012) |
|
| |
| 西島 正弘 |
昭和薬科大学・学長 |
| 生化学 |
Molecular machinery for non-vesicular trafficking of ceramide
K. Hanada, K. Kumagai, S. Yasuda, Y. Miura, M. Kawano, M. Fukasawa, and M. Nishijima
Nature (Article), 426, 803-809, 2003 |
A Potent Adjuvant Monophosphoryl Lipid A Triggers Various Immune Response, but Not Secretion of lL-1・ or Activation of Caspase-1
K. Okemoto, K. Kawasaki, K. Hanada, M. Miura, and M. Nishijima
J. Immunol., 176, 1203-1208, 2006 |
Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide
N. Kudo, K. Kumagai, N. Tomishige, T. Yamaji, S. Wakatsuki, M. Nishijima, K. Hanada, and R. Kato
Proc. Natl. Acad. Sci.USA., 105, 488-493, 2008 |
|
| |
| 早川 堯夫 |
近畿大学薬学総合研究所所長 |
| 生物化学、薬学 |
| バイオ医薬品開発の主流を占める糖タンパク質.バイオ医薬品開発における糖鎖技術（早川堯夫、掛樋一晃、平林 淳監修）、早川堯夫、シーエムシー出版、pp.1-21（2011） |
| Human adipose tissue-derived multilineage progenitor cells exposed to oxidative stress induce neurite outgrowth in PC12 cells through p38 MAPK signaling. Moriyama M, Moriyama H, Ueda A, Nishibata Y, Okura H, Ichinose A, Matsuyama A, Hayakawa T. BMC Cell Biol. 13(1):21（2012） |
| Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4α Transduction. Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, Nonaka A, Sakurai F, Hayakawa T, Kusuda Furue M, Mizuguchi H. Mol Ther. 20(1) 127-137 (2012). |
|
| ○ |
| 堀田 知光 |
国立がん研究センター 理事長 |
| 血液・腫瘍内科学 |
| Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. J Clin Oncol 2011, 29(30): 3990-3998 |
| Phase I and phase II study of azacitidine in Japanese patients with myelodysplastic syndromes. Uchida T, Ogawa Y, Kobayashi Y, Ishikawa T, Ohashi H, Hata T, Usui N, Taniwaki M, Ohnishi K, Akiyama H, Ozawa K, Ohyashiki K, Okamoto S, Tomita A, Nakao S, Tobinai K, Ogura M, Ando K, Hotta T. Cancer Sci. 2011,102(9): 1680-1686 |
| Randomized phase II dose-finding study of weekly administration of darbepoetin alfa in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. Ichinose Y, Steo T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, Saijo N, Hotta T. J Clin Oncol 2010,40(6): 521-529 |
|
| |
| 村井 安 |
Meiji Seika ファルマ
執行役員医薬研究開発本部長 |
| 医薬品開発 |
| 当該年度は該当なし。 |
|
| |
| 渡邉 治雄 |
国立感染症研究所 所長 |
| 細菌学 |
| Interferon-γ-producing immature myeloid cells confer protection against severe invasive group A Streptococcus infections. Takayuki Matsumura, Manabu Ato, Tadayoshi Ikebe, Makoto Ohnishi, Haruo Watanabe ands Kazuo Kobayashi. Nature Communication.DOI:10.1038/ncomms1677. 2012 |
| Coordinate control of the locus of enterocyte effacement and enterohemolysin genes by multiple common virulence regulators in enterohemorrhagic Escherichia coli. Iyoda S, Honda N, Saitoh T, Shimuta K, Terajima J, Watanabe H, Ohnishi M. Infect Immun. 79:4628-4637.2011 |
| Bacterial cytoskeleton protein RodZ is involved in post-transcriptional processing of Shigella type III secretion system. Jiro Mitobe, Itaru Yanagihara, Kiyouhisa Ohnishi, Shoji Yamamoto, Makoto Ohnishi, Akira Ishihama and Haruo Watanabe. EMBO. Rep.12:911-916.2011 |
|
